» Articles » PMID: 34250049

Hypercholesterolemia and Lymphatic Defects: The Chicken or the Egg?

Overview
Date 2021 Jul 12
PMID 34250049
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Lymphatic vessels are necessary for maintaining tissue fluid balance, trafficking of immune cells, and transport of dietary lipids. Growing evidence suggest that lymphatic functions are limited under hypercholesterolemic conditions, which is closely related to atherosclerotic development involving the coronary and other large arteries. Indeed, ablation of lymphatic systems by Chy-mutation as well as depletion of lymphangiogenic factors, including vascular endothelial growth factor-C and -D, in mice perturbs lipoprotein composition to augment hypercholesterolemia. Several investigations have reported that periarterial microlymphatics were attracted by atheroma-derived lymphangiogenic factors, which facilitated lymphatic invasion into the intima of atherosclerotic lesions, thereby modifying immune cell trafficking. In contrast to the lipomodulatory and immunomodulatory roles of the lymphatic systems, the critical drivers of lymphangiogenesis and the details of lymphatic insults under hypercholesterolemic conditions have not been fully elucidated. Interestingly, cholesterol-lowering trials enable hypercholesterolemic prevention of lymphatic drainage in mice; however, a causal relationship between hypercholesterolemia and lymphatic defects remains elusive. In this review, the contribution of aberrant lymphangiogenesis and lymphatic cholesterol transport to hypercholesterolemic atherosclerosis was highlighted. The causal relationship between hypercholesterolemia and lymphatic insults as well as the current achievements in the field were discussed.

Citing Articles

Preventing Breast Cancer-Related Lymphedema: A Comprehensive Analysis of a 9-Year Single-Center Experience of Prophylactic Lymphovenous Bypass.

Cho M, Senger J, Park K, Hansotia K, Chratian S, Kadle R Ann Surg Oncol. 2024; 32(3):2007-2015.

PMID: 39715967 DOI: 10.1245/s10434-024-16640-8.


Calpain and Cardiometabolic Diseases.

Miyazaki T Int J Mol Sci. 2023; 24(23).

PMID: 38069105 PMC: 10705917. DOI: 10.3390/ijms242316782.


Interaction Between Blood Vasculatures and Lymphatic Vasculatures During Inflammation.

Wang S, Zhu X, Wu X, Zhang W, Ding Y, Jin S J Inflamm Res. 2023; 16:3271-3281.

PMID: 37560514 PMC: 10408656. DOI: 10.2147/JIR.S414891.


Identification of diagnostic biomarkers and therapeutic targets in peripheral immune landscape from coronary artery disease.

Feng X, Zhang Y, Du M, Li S, Ding J, Wang J J Transl Med. 2022; 20(1):399.

PMID: 36064568 PMC: 9444127. DOI: 10.1186/s12967-022-03614-1.

References
1.
Tirronen A, Vuorio T, Kettunen S, Hokkanen K, Ramms B, Niskanen H . Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants. Arterioscler Thromb Vasc Biol. 2018; 38(10):2327-2337. DOI: 10.1161/ATVBAHA.118.311549. View

2.
Baldwin M, Halford M, Roufail S, Williams R, Hibbs M, Grail D . Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol. 2005; 25(6):2441-9. PMC: 1061605. DOI: 10.1128/MCB.25.6.2441-2449.2005. View

3.
Sumida H, Noguchi K, Kihara Y, Abe M, Yanagida K, Hamano F . LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood. 2010; 116(23):5060-70. DOI: 10.1182/blood-2010-03-272443. View

4.
Miyazaki T, Akasu R, Miyazaki A . Calpain proteolytic systems counteract endothelial cell adaptation to inflammatory environments. Inflamm Regen. 2020; 40:5. PMC: 7114782. DOI: 10.1186/s41232-020-00114-x. View

5.
Hata S, Abe M, Suzuki H, Kitamura F, Toyama-Sorimachi N, Abe K . Calpain 8/nCL-2 and calpain 9/nCL-4 constitute an active protease complex, G-calpain, involved in gastric mucosal defense. PLoS Genet. 2010; 6(7):e1001040. PMC: 2912385. DOI: 10.1371/journal.pgen.1001040. View